{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.3616.200.110.102.1015",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2022-07-13T01:02:20.000-04:00"
  },
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.1015",
  "version" : "20220713",
  "name" : "Bamlanivimab / Etesevimab Administration",
  "status" : "active",
  "date" : "2022-07-13T01:02:20-04:00",
  "publisher" : "Clinical Architecture",
  "compose" : {
    "include" : [{
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2022",
      "concept" : [{
        "code" : "M0245",
        "display" : "Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring"
      },
      {
        "code" : "M0246",
        "display" : "Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency"
      },
      {
        "code" : "Q0245",
        "display" : "Injection, bamlanivimab and etesevimab, 2100 mg"
      }]
    }]
  },
  "expansion" : {
    "identifier" : "urn:uuid:46ed589e-c3aa-420a-8292-3ed08ba11160",
    "timestamp" : "2022-09-28T05:20:56-04:00",
    "total" : 3,
    "offset" : 0,
    "parameter" : [{
      "name" : "count",
      "valueInteger" : 1000
    },
    {
      "name" : "offset",
      "valueInteger" : 0
    }],
    "contains" : [{
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2022",
      "code" : "M0245",
      "display" : "Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2022",
      "code" : "M0246",
      "display" : "Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
      "version" : "2022",
      "code" : "Q0245",
      "display" : "Injection, bamlanivimab and etesevimab, 2100 mg"
    }]
  }
}